Dynex Technologies

Dynex Technologies

Automates ELISA and chemiluminescence microplates

Overview

Dynex Technologies develops and manufactures fully automated ELISA and chemiluminescence microplate instruments and related accessories. These systems automate the processing of diagnostic tests in laboratories by handling continuous sample loading, performing automated results calculations, and offering an intuitive graphical user interface to minimize training and hands-on time. The products are designed for high-throughput operations and regulatory compliance, supported by software that streamlines workflows and quality controls. Dynex serves a global market with direct sales in the United States and distributor partnerships in over 120 countries, and has installed more than 8,500 instruments worldwide. The company aims to boost laboratory productivity, accuracy, and compliance in the diagnostics field through reliable automation and strong customer service.

About Dynex Technologies

Simplify's Rating
Why Dynex Technologies is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

Hardware

Industrial & Manufacturing

Enterprise Software

Healthcare

Company Size

51-200

Company Stage

N/A

Total Funding

N/A

Headquarters

Chantilly, Virginia

Founded

1952

Get referred to Dynex Technologies

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Dynex claims 1,000 assay protocols and 8,500 global installations.
  • ALPCO partnership opens GI biomarker testing across more laboratories.
  • DS2 Elite launch in January 2026 should lift replacement sales and consumables.

What critics are saying

  • Roche, Abbott, and bioMérieux keep launching broader immunoassay platforms in 2026.
  • Dynex’s 8,500-installed base still depends on aging ELISA demand.
  • Standalone microplate automation faces existential commoditization as multiplex and point-of-care platforms expand.

What makes Dynex Technologies unique

  • January 2026 DS2 Elite deepens Dynex’s automated ELISA workflow.
  • Agility Integra meets 21 CFR Part 11 for regulated labs.
  • ALPCO’s AutoPlex GI panel uses Dynex Multiplier for full automation.

Help us improve and share your feedback! Did you find this helpful?

Growth & Insights and Company News

Headcount

6 month growth

3%

1 year growth

3%

2 year growth

3%
GlobeNewswire
Nov 12th, 2024
Elisa Analyzers Market Size Forecast To Hit Usd 960.7 Million By 2031, Growing At A Cagr Of 5.9%| Says Transparency Market Research, Inc.

Wilmington, Delaware, United States, Transparency Market Research, Inc. , Nov. 12, 2024 (GLOBE NEWSWIRE) -- The ELISA analyzers market was valued at US$ 574.7 million in 2022. Between 2023 and 2031, it is expected to expand at a CAGR of 5.9% and surpass US$ 960.7 million during the forecast period. The development of technology could lead to ELISA analyzers that are more sophisticated and efficient. Faster analysis times, improved automation, and enhanced sensitivity could increase adoption.ELISA (Enzyme-Linked Immunosorbent Assay) is widely used in the medical field and in pharmaceutical research, among other fields

ALPCO
Dec 15th, 2022
5 Reasons to Add GI Biomarker Testing to Your Lab’s Menu

ALPCO has partnered with Dynex Technologies to offer the first automated multiplex GI protein biomarker test.

Recently Posted Jobs

Sign up to get curated job recommendations

There are no jobs for Dynex Technologies right now.

Find jobs on Simplify and start your career today

We update Dynex Technologies's jobs every few hours, so check again soon! Browse all jobs →